{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:48:53Z","timestamp":1792028933176,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.schres.2017.06.030","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T05:31:47Z","timestamp":1499319107000},"page":"126-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"193","author":[{"given":"Mong-Liang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsiu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2017.06.030_bb0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1176\/appi.ajp.2008.08071065","article-title":"Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus","volume":"166","author":"Andersohn","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.06.030_bb0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2008.10.023","article-title":"Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients","volume":"108","author":"Bai","year":"2009","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.06.030_bb0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/schbul\/21.4.579","article-title":"Clozapine: efficacy and safety","volume":"21","author":"Buchanan","year":"1995","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2017.06.030_bb0020","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2125.2009.03476.x","article-title":"In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation","volume":"68","author":"Chetty","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.schres.2017.06.030_bb0025","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.06.030_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0006-8993(03)02351-5","article-title":"Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism","volume":"971","author":"Dwyer","year":"2003","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.schres.2017.06.030_bb0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2125.1997.t01-1-00605.x","article-title":"The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine","volume":"44","author":"Eiermann","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2017.06.030_bb0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/00004714-200012000-00024","article-title":"Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner","volume":"20","author":"Fabrazzo","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2017.06.030_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1749-6632.1989.tb53229.x","article-title":"Depression, antidepressants, and body weight change","volume":"575","author":"Fernstrom","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"8","key":"10.1016\/j.schres.2017.06.030_bb0050","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.transproceed.2003.10.058","article-title":"Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients","volume":"35","author":"Florea","year":"2003","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.schres.2017.06.030_bb0055","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2017.06.030_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199500291-00003","article-title":"Overview of the pharmacokinetics of fluvoxamine","volume":"29","author":"van Harten","year":"1995","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.schres.2017.06.030_bb0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1871524910909030197","article-title":"Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship","volume":"9","author":"Hashimoto","year":"2009","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"issue":"10","key":"10.1016\/j.schres.2017.06.030_bb0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/bmc.514","article-title":"Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescence detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole","volume":"19","author":"Higashi","year":"2005","journal-title":"Biomed. Chromatogr."},{"issue":"2","key":"10.1016\/j.schres.2017.06.030_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002139900351","article-title":"Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight","volume":"149","author":"Hinze-Selch","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2017.06.030_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fendo.2012.00012","article-title":"Fluvoxamine attenuated endoplasmic reticulum stress-induced leptin resistance","volume":"3","author":"Hosoi","year":"2012","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.schres.2017.06.030_bb0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.06.030_bb0090","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4088\/JCP.10r06264yel","article-title":"Past and present progress in the pharmacologic treatment of schizophrenia","volume":"71","author":"Kane","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.06.030_bb0095","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.06.030_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.schres.2017.06.030_bb0105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00406-013-0406-3","article-title":"Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials","volume":"263","author":"Kishi","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2017.06.030_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2007.05.004","article-title":"Pharmacology of N-desmethylclozapine","volume":"115","author":"Lameh","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.schres.2017.06.030_bb0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-2007-979196","article-title":"Coadministration of clozapine and fluvoxamine in psychotic patients\u2014clinical experience","volume":"32","author":"Lammers","year":"1999","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.06.030_bb0120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/YIC.0b013e3283277627","article-title":"Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients","volume":"24","author":"Lee","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2017.06.030_bb0125","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.06.030_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"8","key":"10.1016\/j.schres.2017.06.030_bb0135","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4088\/JCP.v61n0809","article-title":"Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients","volume":"61","author":"Lu","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.06.030_bb0140","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","article-title":"Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances","volume":"65","author":"Lu","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.06.030_bb0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/11533280-000000000-00000","article-title":"The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications","volume":"24","author":"McIntyre","year":"2010","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2017.06.030_bb0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/WNF.0b013e31818d46f5","article-title":"N-desmethylclozapine: is there evidence for its antipsychotic potential?","volume":"32","author":"Mendoza","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2017.06.030_bb0155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2017.06.030_bb0160","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.06.030_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00004850-200505000-00007","article-title":"An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels","volume":"20","author":"Ng","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2017.06.030_bb0170","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","article-title":"Optimizing clozapine treatment","volume":"123","author":"Nielsen","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.schres.2017.06.030_bb0175","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2174\/138161212799436476","article-title":"Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases","volume":"18","author":"Niitsu","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.schres.2017.06.030_bb0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1017\/S1461145708009619","article-title":"Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene","volume":"12","author":"Nonogaki","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.06.030_bb0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00004714-200002000-00007","article-title":"Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism","volume":"20","author":"Olesen","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.06.030_bb0190","first-page":"345","article-title":"Acute effects of clozapine-fluvoxamine combination","volume":"79","author":"Peritogiannis","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.06.030_bb0195","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.06.030_bb0200","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00213-015-4161-1","article-title":"The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review","volume":"233","author":"Polcwiartek","year":"2016","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2017.06.030_bb0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2011.08.005","article-title":"Clozapine resistance: augmentation strategies","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.06.030_bb0210","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J. Psychiatry Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2017.06.030_bb0215","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-012-2922-7","article-title":"Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?","volume":"225","author":"Remington","year":"2013","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2017.06.030_bb0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.pnpbp.2005.03.019","article-title":"The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment","volume":"29","author":"Reynolds","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.06.030_bb0225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2017.06.030_bb0230","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1248\/bpb.31.2250","article-title":"Fluvoxamine inhibits weight gain and food intake in food restricted hyperphagic Wistar rats","volume":"31","author":"Shinozaki","year":"2008","journal-title":"Biol. Pharm. Bull."},{"issue":"7","key":"10.1016\/j.schres.2017.06.030_bb0235","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0006-3223(96)00170-9","article-title":"Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study","volume":"40","author":"Silver","year":"1996","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.06.030_bb0240","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nurt.2008.10.034","article-title":"Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?","volume":"6","author":"Silver","year":"2009","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.schres.2017.06.030_bb0245","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/chi.0b013e31812eed10","article-title":"Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome","volume":"46","author":"Sporn","year":"2007","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.06.030_bb0250","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","article-title":"Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia","volume":"173","author":"Stroup","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.06.030_bb0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oxfordjournals.schbul.a006989","article-title":"Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial","volume":"29","author":"Swartz","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2017.06.030_bb0260","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-2007-979221","article-title":"Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial","volume":"32","author":"Szegedi","year":"1999","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.schres.2017.06.030_bb0265","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.06.030_bb0270","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0378-4347(92)80554-4","article-title":"Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection","volume":"583","author":"Weigmann","year":"1992","journal-title":"J. Chromatogr."},{"issue":"1\u20132","key":"10.1016\/j.schres.2017.06.030_bb0275","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2017.06.030_bb0280","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-199802000-00002","article-title":"Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study","volume":"18","author":"Wetzel","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.06.030_bb0285","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1067\/mcp.2001.119724","article-title":"Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2","volume":"70","author":"Yao","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.schres.2017.06.030_bb0290","first-page":"346","article-title":"Effect of fluvoxamine on total serum cholesterol levels during weight reduction","volume":"57","author":"de Zwaan","year":"1996","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T14:00:26Z","timestamp":1659189626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417303687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":58,"alternative-id":["S0920996417303687"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.06.030","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}